par Yernault, Jean Claude 
Référence Revue médicale de Bruxelles, 15, 4, page (277+280-281)
Publication Publié, 1994
Référence Revue médicale de Bruxelles, 15, 4, page (277+280-281)
Publication Publié, 1994
Article révisé par les pairs
| Résumé : | There are two families of inhaled bronchodilators: β-2-mimetics and vagolytics. They are equally effective in patients with chronic obstructive pulmonary disease (COPD), whereas β-mimetics are usually superior in asthmatics. The clinical benefits linked to long acting β-mimetics like salmeterol are already established in asthmatics. Metered dose aerosols remain the most widely used type of inhaler, eventually connected to a spacer, together with powder inhalers. Usual bronchodilators are now prescribed on demand rather than on a regular basis. There is no proof that β-mimetics are causally related to asthma deaths. Inhaled corticosteroids, which have no acute bronchospasmolytic properties, are the first-choice chronic drug treatment of moderate to severe asthma; they are currently being evaluated in COPD. |
